Public Company News
MediaTek Collaborates with NVIDIA on the RTX Spark to Power the Next Wave of Windows PC Experiences
MediaTek brings its design expertise in CPU performance and power efficiency to the groundbreaking RTX Spark, bringing local personal agents, advanced content creation, and gaming together in small, ultra-efficient Windows PCs TAIPEI, June 1, 2026 /PRNewswire/ -- MediaTek today announced its role...
2026-06-01 13:30
XPENG Announces Vehicle Delivery Results for May 2026
GUANGZHOU, China, June 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for May 2026. XPENG delivered a total of 32,158 vehicles in May, representing a 4% increas...
2026-06-01 12:47
1
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)
Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications SEOUL, South Korea, May 31, 2026 /PRNewswire/ -- Hanmi Pharm. Co., Ltd. ("Hanmi")today announced that they have entered into a license agreement for the development, manufacturing and commercialization of Hanmi's b...
2026-06-01 11:09
828
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting
SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...
2026-06-01 08:15
1084
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept
First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...
2026-06-01 08:15
1493
2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC
* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...
2026-06-01 08:00
921
2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer
* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...
2026-06-01 08:00
1308
HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...
2026-05-31 21:00
1461
Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...
2026-05-31 08:09
2558
CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements
HONG KONG, May 29, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the "Notification Letter") from Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2026, indicating th...
2026-05-30 08:16
2454
Lanvin Names Barbara Werschine as CEO
SHANGHAI, May 29, 2026 /PRNewswire/ -- Lanvin Group (NYSE: LANV), a global luxury fashion group, today announced that Maison Lanvin, the oldest couture house in Paris, has appointed Barbara Werschine as Chief Executive Officer. Ms. Werschine is an accomplished leader in the international luxury s...
2026-05-29 22:29
2702
Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering
SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds ...
2026-05-29 22:00
4839
Acer Unveils Sub-1kg TravelMate P6 14 AI Business Laptop with New Acer Comfort Touch Design for Premium Luxury on the Move
Lineup also deploys new Intel Core Series 3 processors on business laptops for the first time across form factors Editor's Summary * The Acer TravelMate P6 14 AI is a Windows 11 Copilot+ PC powered by Intel Core Ultra Series 3 processors with Intel vPro, delivering 150 TOPS of platform AI pow...
2026-05-29 21:30
3836
New Acer Tablets Plus AI and AR Glasses Expand On-the-Go Capabilities
Editor's Summary * The Acer Iconia Duo S14 is a premium 14.2-inch 2.8K 3:2 OLED tablet powered by the MediaTek Dimensity 8300 SoC and Android 16, designed as the ultimate creative and productivity hub for elite professionals. * The Acer Iconia Duo S12 is a 12.2-inch 2.8K 3:2 OLED premium tabl...
2026-05-29 21:25
3277
Acer Introduces Predator Helios 18 AI: The Ultimate Gaming Laptop
Gaming lineup also includes the Acer Nitro 16 laptop, the Acer Nitro Blaze Link streaming handheld device, and accessories for leveling up gaming experiences Editor's Summary * Winner of the iF Design Award 2026, the Predator Helios 18 AI gaming laptop delivers ultimate performance with up to ...
2026-05-29 21:10
2349
Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions
SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in ...
2026-05-29 21:08
3074
Acer Expands Lineup of Aspire AI Copilot+ PCs With New Laptops and All-in-Ones
Editor's Summary * The Acer Aspire X 16 AI laptop includes up to the latest Intel Core Ultra X9 processors with up to 180 platform TOPS, multi-day battery life, advanced cooling, and a thin-and-light chassis. * The Acer Aspire 18 AI laptop combines the performance of Intel Core Ultra Series ...
2026-05-29 21:05
2831
Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer
* ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins * WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen...
2026-05-29 20:52
2614
LEIFRAS Co., Ltd. Achieves 45% Growth in After-School Day Care Network, Expanding from 20 to 29 Locations Nationwide
Expanding Developmental Support Services Through Organic Growth and Strategic M&A TOKYO, May 29, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social business company dedicated to youth sports and community engagement, today announced the strateg...
2026-05-29 20:30
4278
SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
* SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth Fund financing program * SK bioscience became the first Korean novel drug and vaccine deve...
2026-05-29 20:00
2199
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 287 media titles]
2026-05-27 09:16
Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
6965
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
6010
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
5997
